🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against superbug strains of the pathogen, according to health experts.

A Global Health Concern

Gonorrhoea infections are increasing globally, with figures suggesting in excess of 82 million new cases annually. Particularly high rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the context of rising global incidence, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Medical experts are deeply concerned about the increase in drug-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

Zoliflodacin, also known as Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists hope that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, was also approved in the same week. This drug, which is also used to treat urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This milestone signifies a major breakthrough in the management of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Testing Data and Global Access

Based on data published in a major medical journal, the new drug eradicated more than 90% of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which uses an injection and a pill. The study included hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the rights to make available and distribute the drug in many regions with limited resources.

Medical professionals directly involved have voiced positive views. The availability of a easy-to-administer therapy such as this is seen as a "critical tool" for managing the epidemic. This is considered crucial to reduce the burden of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.